ArticleUrologia internationalis2026
Association of the Modified Glasgow Prognostic Score with Overall Survival in Immunotherapy-Treated Metastatic Urothelial Carcinoma: A Single-Center Cohort Study.
Article in Urologia internationalis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGrowing evidence suggests that a persistent systemic inflammatory response is associated with poorer survival outcomes in patients with malignant disease. The modified Glasgow Prognostic Score (mGPS), based on elevated C-reactive protein (CRP >10 mg/L) and hypoalbuminemia (<35 g/L), has been established as an independent prognostic marker in various cancers. The aim of this study was to evaluate the prognostic value of the mGPS in patients with metastatic urothelial carcinoma of the bladder (mUC) receiving immunotherapy, with particular focus on treatment response, tolerability, and overall survival (OS).
methodsIn this retrospective single-center cohort study, 48 patients with mUC treated with immune checkpoint inhibitors were included. Patients received immunotherapy either due to ineligibility for platinum-based chemotherapy or as second-line treatment following disease progression. Pretreatment mGPS was categorized into 3 groups: mGPS 0 (CRP <10 mg/L), mGPS 1 (CRP >10 mg/L, albumin ≥35 g/L), and mGPS 2 (CRP >10 mg/L, albumin <35 g/L). OS and disease-free survival (DFS) were analyzed using the Kaplan-Meier estimates. Treatment-related toxicity was assessed according to Common Terminology Criteria for Adverse Event criteria. Prognostic factors were evaluated using univariate Cox regression analyses.
resultsSurvival outcomes differed significantly across mGPS categories, with patients classified as mGPS 0 demonstrating the most favorable treatment response and survival. In univariate analysis, both mGPS (p < 0.0001) and tumor stage (p = 0.004) were significantly associated with prognosis. Response rates to immunotherapy varied markedly between groups (mGPS 0: 71%, mGPS 1: 34%, mGPS 2: 26%; p < 0.001). Higher mGPS values were also significantly associated with increased treatment-related and disease-related morbidity.
conclusionSystemic inflammation and nutritional status, as reflected by the mGPS, are independent predictors of treatment response, toxicity, and survival in patients with mUC undergoing immunotherapy. Alongside established pathological markers, the mGPS represents an objective, low-cost, and readily available prognostic tool with potential clinical utility in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.